We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.
- Authors
Idris, Iskandar; Donnelly, Richard
- Abstract
Exploiting the incretin effect to develop new glucose-lowering treatments has become the focus of intense research. One successful approach has been the development of oral inhibitors of dipeptidyl peptidase-IV (DPP-IV). These drugs reversibly block DPP-IV-mediated inactivation of incretin hormones, for example, glucagon-like peptide 1 (GLP-1) and also other peptides that have alanine or proline as the penultimate N-terminal amino acid. DPP-IV inhibitors, therefore, increase circulating levels and prolong the biological activity of endogenous GLP-1, but whether this is sufficient to fully explain the substantial reduction in haemoglobin A1c (HbA1c) and associated metabolic profile remains open to further investigation. DPP-IV inhibitors such as vildagliptin and sitagliptin have been shown to be highly effective antihyperglycaemic agents that augment insulin secretion and reduce glucagon secretion via glucose-dependent mechanisms. This review summarizes the major clinical trials with DPP-IV inhibitors as monotherapy and as add-on therapy in patients with type 2 diabetes. The magnitude of HbA1c reduction with DPP-IV inhibitors depends upon the pretreatment HbA1c values, but there seems to be no change in body weight, and very low rates of hypoglycaemia and gastrointestinal disturbance with these agents. DPP-IV inhibitors represent a major new class of oral antidiabetic drug and their metabolic profile offers a number of unique clinical advantages for the management of type 2 diabetes.
- Subjects
CD26 antigen; HYPOGLYCEMIC agents; TYPE 2 diabetes; ALANINE; CLINICAL trials
- Publication
Diabetes, Obesity & Metabolism, 2007, Vol 9, Issue 2, p153
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/j.1463-1326.2007.00705.x